Monash IVF Group Stabilises in 1H26 While Advancing Strategic Reset.
Monash IVF Group Limited (ASX: MVF) delivered a steadier first half in FY26 following earlier operational disruption, although financial performance remained below the prior corresponding period. Revenue eased to AU$137.9 million, with Underlying EBITDA declining to AU$30.2 million and Underlying NPAT to AU$10.4 million. The result reflected softer stimulated cycle volumes and a reduction in domestic market share to 19.0%, influenced by industry weakness and brand-related pressures.
Despite lower volumes, clinical outcomes continued to strengthen, with pregnancy rates for women under 43 improving to 40.7%, demonstrating sustained scientific and operational capability. International operations showed resilience, with growth across Singapore, Bali, and Johor Bahru, while genetics services recorded solid momentum, particularly in PGT-related activity.
Management reaffirmed full-year Underlying NPAT guidance of AU$20.0 million. Capital expenditure is expected to moderate in the second half as major infrastructure projects near completion, with leverage projected to remain around 2.0x. Strategic priorities centre on restoring domestic performance, expanding genetics, enhancing leadership alignment, and driving sustainable organic growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Monash IVF Group Stabilises in 1H26 While Advancing Strategic Reset.
Monash IVF Group Limited (ASX: MVF) delivered a steadier first half in FY26 following earlier operational disruption, although financial performance remained below the prior corresponding period. Revenue eased to AU$137.9 million, with Underlying EBITDA declining to AU$30.2 million and Underlying NPAT to AU$10.4 million. The result reflected softer stimulated cycle volumes and a reduction in domestic market share to 19.0%, influenced by industry weakness and brand-related pressures.
Despite lower volumes, clinical outcomes continued to strengthen, with pregnancy rates for women under 43 improving to 40.7%, demonstrating sustained scientific and operational capability. International operations showed resilience, with growth across Singapore, Bali, and Johor Bahru, while genetics services recorded solid momentum, particularly in PGT-related activity.
Management reaffirmed full-year Underlying NPAT guidance of AU$20.0 million. Capital expenditure is expected to moderate in the second half as major infrastructure projects near completion, with leverage projected to remain around 2.0x. Strategic priorities centre on restoring domestic performance, expanding genetics, enhancing leadership alignment, and driving sustainable organic growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au